New Delhi: Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator for the expanded use of RYALTRIS nasal spray used for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years.
Glenmark Specialty SA has received approval from the US Food and Drug Administration for the expanded use of RYALTRIS -- olopatadine hydrochloride and mometasone furoate -- nasal spray of strength 665 mcg/25 mcg per spray, Glenmark Pharmaceuticals said in a regulatory filing.
